Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a UK multicenter prospective study (TRACC)

被引：23

作者：

Anandappa, Gayathri ^{[1
]}

Starling, Naureen ^{[2
,3
]}

Begum, Ruwaida ^{[4
,5
]}

Bryant, Annette ^{[4
,5
]}

Sharma, Shruti ^{[6
]}

Renner, Derrick ^{[6
]}

Aresu, Maria ^{[5
]}

Peckitt, Clare ^{[4
,5
]}

Sethi, Himanshu ^{[6
]}

Feber, Andrew ^{[7
]}

Potter, Vanessa Alice ^{[8
]}

Paraoan, Marius ^{[9
]}

Abulafi, Muti ^{[10
]}

George, Nicol ^{[11
]}

Branagan, Graham ^{[12
]}

Duff, Sarah ^{[13
]}

West, Nicholas ^{[14
]}

Aleshin, Alexey ^{[6
]}

Chau, Ian ^{[15
]}

Cunningham, David ^{[16
]}

机构：

[1] Royal Marsden NHS Fdn Trust, London, England

[2] Royal Marsden Hosp NHS Fdn Trust, London, England

[3] Royal Marsden Hosp NHS Fdn Trust, Surrey, England

[4] Royal Marsden NHS Fdn Trust, London, England

[5] Royal Marsden NHS Fdn Trust, Surrey, England

[6] Natera Inc, San Carlos, CA USA

[7] Inst Canc Res, Sutton, Surrey, England

[8] Univ Hosp Coventry & Warwickshire, Coventry, W Midlands, England

[9] Wigan & Leigh NHS Fdn Trust, Wigan, England

[10] Croydon Univ Hosp, London, England

[11] Southend Univ Hosp, Westcliff On Sea, Essex, England

[12] Salisbury NHS Fdn Trust, Salisbury, Wilts, England

[13] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England

[14] Epsom & St Helier NHS Fdn Trust, Epsom, Surrey, England

[15] Royal Marsden Hosp NHS Fdn Trust, London, England

[16] Royal Marsden Hosp, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

102

引用

页数：2

共 50 条

[1] A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
Srinivasan, G.
Hubert, A.
Purim, O.
Semenisty, V.
Lo, N.
Tsukada, Y.
Mondello, G.
Cubillo, A.
Subramaniam, S.
Palomares, M. R.
Baehner, R. F. L.
De Jong, F.
Kerr, D. J.
Yoshino, T.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S69 - S70
[2] Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
Slater, Susanna
Bryant, Annette
Aresu, Maria
Begum, Ruwaida
Chen, Hsiang-Chi
Peckitt, Clare
Lazaro-Alcausi, Retchel
Carter, Paul
Anandappa, Gayathri
Khakoo, Shelize
Branagan, Graham
George, Nicol
Abulafi, Muti
Duff, Sarah
West, Nicholas
Bucheit, Leslie
Rich, Thereasa A.
Chau, Ian
Starling, Naureen
Cunningham, David
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 169 - 169
[3] Plasma-informed minimal residual disease (MRD) assay: A multicenter prospective study in Japanese patients with stage II colorectal cancer
Oki, Eiji
Ando, Koji
Hisamatsu, Yuichi
Nakanishi, Ryota
Nakaji, Yu
Kudou, Kensuke
Kusumoto, Tetsuya
Kagawa, Yoshinori
Ung, Weng Chit
Niiro, Hayato
Tada, Sachiyo
Hirose, Takashi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[4] INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
Maddalena, Giulia
Pellatt, Andrew Jared
Eluri, Madhulika
Parseghian, Christine Megerdichian
Aziz, Kathryn
Alfaro, Kristin
Kell, Robert J.
Bent, Alisha Heather
Huey, Ryan W.
Uppal, Abhineet
Konishi, Tsuyoshi
Overman, Michael J.
Morelli, Maria Pia
Willis, Jason
Shen, John Paul Y. C.
Raghav, Kanwal Pratap Singh
Newhook, Timothy E.
Morris, Van K.
Dasari, Arvind
Kopetz, Scott
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 27 - 27
[5] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
Akagunduz, Baran
Guven, Deniz Can
Ozer, Muhammet
Okten, Ilker Nihat
Atag, Elif
Unek, Ilkay Tugba
Tatli, Ali Murat
Karaoglu, Aziz
[J]. JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
[6] Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study
Alshibany, Aisha
Zhou, Maggie
Warren, Emilie Ak
Ganjoo, Kristen N.
Demicco, Elizabeth
Feeney, Jordan
Lee, Jasmine
Shultz, David Benjamin
Spickard, Erik
Bui, Nam
Cardona, Kenneth
Salawu, Abdulazeez
Razak, Albiruni Ryan Abdul
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)
Isbell, James M.
Goldstein, Jordan Scott
Hamilton, Emily G.
Liu, Si-Yang
Eichholz, Jordan
Buonocore, Darren J.
Rusch, Valerie W.
Bott, Matthew
Molena, Daniela
Rocco, Gaetano
Yang, Soo-Ryum
Rudin, Charles M.
Jones, David R.
Roff, Alanna
Schultz, Andre
Chabon, Jake J.
Kurtz, David Matthew
Alizadeh, Ash A.
Li, Bob T.
Diehn, Maximilian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
Chakrabarti, Sakti
Kasi, Anup Kumar
Parikh, Aparna R.
Mahipal, Amit
[J]. CANCERS, 2022, 14 (13)
[9] Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay
Parikh, A.
van Seventer, E.
Boland, G.
Siravegna, G.
Hartwig, A.
Jaimovich, A.
Raymond, V. M.
Talasaz, A.
Corcoran, R. B.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S419 - S419
[10] The application of circulating tumor DNA for minimal residual disease detection in colorectal cancer
Chan, Hiu Ting
Nagayama, Satoshi
Chin, Yoon Ming
Otaki, Masumi
Hayashi, Rie
Fukunaga, Yosuke
Ueno, Masashi
Nakamura, Yusuke
Low, Siew-Kee
[J]. CANCER SCIENCE, 2021, 112 : 526 - 526

← 1 2 3 4 5 →